Inovio Pharmaceuticals is changing the vaccine sector, using vaccines to prevent and treat cancers and challenging infectious diseases. Its synthetic SynCon vaccines are designed to provide universal cross-strain protection against strains of pathogens such as influenza. The company's vaccines, in conjunction with its proprietary electroporation delivery, have been shown to humans to generate best-in-class immune response with a favorable safety profile.
The company has been named by the Philadelphia Business Journal as the "Best Mid-Stage Product Development Company" by a panel of judges from leading companies and universities in the state of Pennsylvania. This naming was part of the Journal's Life Sciences Awards, an annual program recognizing the region's medical miracle makers for their innovative approaches to improving the delivery of health care.
Inovio Pharmaceuticals was chosen for the prestigious award by the judges for "the accomplishments of a company that has important new therapies in the clinical trial stage of development." This recognition was based on the firm's pipeline of synthetic preventive and therapeutic vaccines to treat or prevent cancer, HIV, influenza, and other infectious diseases.
The company has vaccines in phase II trials, including vaccines for cervical cancer, acute and chronic myeloid leukemia, and hepatitus C virus. It also has vaccines in phase I trials for HIV (Clade A, B, C) and various strains influenza (H1N1, H5N1).
For additional information about Inovio Pharmaceuticals, its vaccines, and the clinical trials, please visit www.inovio.com
Please see disclaimer on the MissionIR website http://www.missionir.com/disclaimer.html